April 20, 2026
MSD secures EC approval for Enflonsia to prevent infant RSV infection
Merck & Co (MSD) has received the European Commission (EC) approval for Enflonsia (clesrovimab), indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their initial RSV season.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







